跳至主要内容
临床试验/NCT07032116
NCT07032116尚未招募不适用

Evidence-based Evaluation of Yiqi Jiangzhuo Huoxue Tongluo Method in Delaying the Occurrence of End-stage Renal Disease in Diabetic Kidney Disease--Study 1

Liu Hongfang5 个研究点 分布在 1 个国家目标入组 4,472 人开始时间: 2025年8月1日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
4,472
试验地点
5
主要终点
The incidence of end-stage renal disease

研究概览

简要总结

In order to reduce the clinical demand for kidney dialysis rate of Diabetic Kidney Disease(DKD) patients, a bidirectional cohort study of 4472 patients with DKD (Qi deficiency and collateral stasis syndrome) was carried out based on a preliminary DKD cohort of 13,000 patients. The exposure factor was supplementing and reducing the kidney turbidity-Huoxue Tongluo method represented by the addition and subversion of Shenzhuo prescription, and the incidence of end-stage renal disease was the main therapeutic index. Follow-up was conducted for 2 years

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Other

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •1 in line with Western medicine diagnostic criteria for type 2 diabetic kidney disease ;
  • •2 18-80 years old, regardless of gender ;
  • •3 eGFR > 15ml / ( min · 1.73m2 ) ; the eGFR was calculated according to the chronic kidney disease epidemiology collaboration equation ( CKD-EPI ).
  • •4 In line with the diagnostic criteria of qi deficiency and collateral stasis syndrome in traditional Chinese medicine ;
  • •5glycosylated hemoglobin ( HbA1c ) between 7-10 % ;
  • •6 blood pressure ≤ 160 / 100mmHg ;
  • •7 to sign the informed consent ;

排除标准

  • •1 combined with other clear renal diseases, such as polycystic kidney disease, glomerulonephritis, renal tumor, etc. ;
  • •2 patients with a history of recurrent genitourinary tract infection ;
  • •3 combined with cardiovascular and cerebrovascular, digestive, respiratory, urinary, immune system serious diseases or mental diseases ;
  • •4 currently in pregnancy, lactation, or pregnancy plan women ;
  • •5 Patients with type 1 diabetes.
  • •6 Tumor patients undergoing radiotherapy, chemotherapy or targeted therapy.

结局指标

主要结局

The incidence of end-stage renal disease

时间窗: Review period, enrollment, enrollment two months, enrollment half a year, enrollment 1 year, enrollment 1 and a half years, enrollment two years

dialysis, transplantation or glomerular filtration rate ( eGFR ) \< 15ml / ( min · 1.73m2 )

次要结局

  • Estimate the change value of glomerular filtration rate ( eGFR ) level, slope(Review period, enrollment, enrollment two months, enrollment half a year, enrollment 1 year, enrollment 1 and a half years, enrollment two years)
  • Incidence of renal composite outcome indicators(Review period, enrollment, enrollment two months, enrollment half a year, enrollment 1 year, enrollment 1 and a half years, enrollment two years)
  • Changes of urinary protein creatinine ratio(Review period, enrollment, enrollment two months, enrollment half a year, enrollment 1 year, enrollment 1 and a half years, enrollment two years)
  • Changes of 24-hour urinary protein level(Review period, enrollment, enrollment two months, enrollment half a year, enrollment 1 year, enrollment 1 and a half years, enrollment two years)
  • Chinese medicine syndrome scores(Review period, enrollment, enrollment two months, enrollment half a year, enrollment 1 year, enrollment 1 and a half years, enrollment two years)

研究者

发起方
Liu Hongfang
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Liu Hongfang

Chief Physician

Dongzhimen Hospital, Beijing

研究点 (5)

Loading locations...

相似试验

YiqiJiangzhuoHuoxueTongluo Method to Delay the... | 临床试验